Key statistics
As of last trade, Ultimovacs ASA (7UM:DEU) traded at 0.142, 21.37% above the 52 week low of 0.117 set on Sep 19, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.1324 |
---|---|
High | 0.169 |
Low | 0.132 |
Bid | 0.1376 |
Offer | 0.183 |
Previous close | 0.138 |
Average volume | 1.99k |
---|---|
Shares outstanding | 34.41m |
Free float | 20.67m |
P/E (TTM) | -- |
Market cap | 65.37m NOK |
EPS (TTM) | -5.21 NOK |
Data delayed at least 15 minutes, as of Sep 23 2024.
More ▼
Announcements
- Ultimovacs Announces Patient Recruitment Discontinuation in LUNGVAC Trial Investigating UV1 Combined with Checkpoint Inhibitor Therapy in Non-Small Cell Lung Cancer
- Ultimovacs Announces Updated Data Analysis on UV1 Phase II NIPU Trial in Mesothelioma at ESMO 2024
- Ultimovacs ASA Reports Second Quarter 2024 Financial Results and Provides General Business Update
- Ultimovacs ASA: Invitation to second quarter 2024 results webcast presentation
- Ultimovacs Announces Notice of Resignation from Deputy Board Member
- Ultimovacs Announces Topline Data from FOCUS Phase II Trial of UV1 Combined with Pembrolizumab in Patients with Metastatic or Recurrent Head and Neck Cancer
- Ultimovacs Announces Poster Presentation of NIPU Phase II Trial Update at Upcoming ESMO Congress 2024
- Ultimovacs ASA announces revised terms of the employee share option program
- Ultimovacs provides update from Phase I study in malignant melanoma: Continued strong overall survival in patients treated with UV1 cancer vaccine and pembrolizumab
- Ultimovacs Announces Poster Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
More ▼